The elderly who received the second Pfizer vaccine twelve weeks later produced more antibodies than those three weeks between the two injections.It is obvious Learn Researchers from the University of Birmingham.
175 people participated. The research has not been peer-reviewed and has not yet been published in a scientific journal.
Among the respondents in their 80s, who received the so-called Booster After twelve weeks, the amount of antibody was finally 3.5 times higher than that of the same age who received the second injection three weeks later.
In the UK, there was an initial three-week gap between the first and second vaccination. In order to extend the vaccination time, more people can be vaccinated faster. This has also happened in the Netherlands. Here, the time between the first and second injection is now five to six weeks.
Anke Huckriede, professor of vaccinology at the University of Groningen, replied: “Obviously it works very well.” “Of course you hope that this applies to young people. To do this, more research is needed, and it is necessary to know whether the results are also applicable to others. mRNA vaccine.
Pfizer’s vaccine is an mRNA vaccine, but there are also so-called carrier vaccines. They work differently. understand more? In this video (since January), Marjolein van Egmond of Amsterdam UMC explains the difference:
Pfizer Medical Director Marc Kaptein speaks on the radio program One to one A “very interesting study”. He did say that more research is needed to conclude that extending the interval between injections can actually increase the effectiveness of the vaccine.
He pointed out that in this study, the number of T cells measured in the elderly was relatively small. T cells are cells that recognize viruses. “If you have to wait 12 weeks for the second injection, the advantage of this is that the number of antibodies will increase. But it also has a disadvantage, that is, the effect of T cells will become worse.”
Kaptein said it is not clear what the results of the study mean in the expected time between injections. For example, he does not rule out that the time currently used in the Netherlands between two injections happens to be a period when the antibody response and T cell response are both good.
A spokesperson for the British Ministry of Health said that after the investigation in the UK, the Ministry of Health and RIVM will have a dialogue. “The University of Birmingham’s research contains new insights, which is why we are engrossed in it. Therefore, we will discuss with RIVM. On this basis, possible next steps can be determined.”